Sanofi Pasteur ends vaccine JV with MSD


Sanofi Pasteur has ended its vaccine joint venture (JV) with MSD (known as Merck & Co in the US and Canada), Sanofi Pasteur MSD (SPMSD).

Both companies will integrate their respective vaccines business in Europe into their operations and separately pursue their own vaccine strategies within the region.

The project was announced in March last year and since then it has been managed in an open dialogue with the SPMSD employees, unions and relevant external stakeholders.

Sanofi Pasteur and MSD had jointly stated: “After carefully considering our individual strategic priorities, alongside the economic and regulatory environments for vaccine operations in the European Union, we have mutually agreed that it is in our best interests to manage our vaccine product portfolios independently.

“We believe that focusing our efforts on opportunities unique to our respective companies will better position us to drive growth, execute in a more efficient manner and optimise vaccine coverage.”

"Both companies will integrate their respective vaccines business in Europe into their operations and separately pursue their own vaccine strategies within the region."

Following the completion of the JV, each company will now be able to define its own vaccines strategy.

Sanofi announced in November 2015 that it would reshape its portfolio as part of its Strategic Roadmap 2020.

Sanofi Pasteur is the vaccines division of Sanofi and provides more than one billion doses of vaccine each year.

Owned on a 50/50 basis by Sanofi Pasteur and MSD, the Sanofi Pasteur MSD JV was created in 1994 to develop and commercialise vaccines originating from both companies’ pipelines to promote public health in 19 European countries.


Image: Sanofi Pasteur is the vaccines division of Sanofi. Photo: courtesy of Sanofi.